Optimized cardiovascular risk in peripheral arterial disease - does intensified statin therapy matter?
Optimized cardiovascular risk in peripheral arterial disease - does intensified statin therapy matter? Vasa. 2019 Jul;48(4):371-372 Authors: Sonnenschein K, Tongers J PMID: 31232678 [PubMed - in process]
Clinical Liver Disease, Volume 15, Issue 1, Page 40-45, January 2020.
Purpose of review To review the recent evidence from observational/genetic/interventional studies addressing triglycerides and residual cardiovascular risk (CVRisk). Recent findings Large population-based and secondary prevention studies consistently show an association of higher triglycerides with increased CVRisk. This is compounded by genetic studies demonstrating an independent relationship between triglyceride raising or lowering genetic variants affecting triglyceride-rich lipoproteins (TRL) metabolism and CVRisk. Mendelian randomization analysis suggests the benefit of genetic lowering of triglycerides and LDL-...
The pairing of two LDL-C-lowering agents called Nexlizet is indicated for use on top of statins to help adults with established ASCVD or heterozygous familial hypercholesterolemia reach their goals.FDA Approvals
CONCLUSIONS: Heterozygous FH is associated with increased risk for stroke, PAD and AoVC. Clinicians should take these non-CHD ASCVD aspects into consideration for optimal management of FH patients. PMID: 32096673 [PubMed - as supplied by publisher]
An electronic algorithm was used to flag patients with HCV risk markers for testing Related items fromOnMedica Widespread hepatitis C screening may do more harm than good Earlier transplants for liver disease kids may cut brain damage risk Significant fall in Hepatitis C deaths Doctors urge government to act on rising alcohol impact Benefits of statins 'still outweigh risks'
Previous studies on statins ’ effect on survival of patients with pancreatic ductal adenocarcinoma (PDAC) report conflicting results.
Publication date: Available online 26 February 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Ben Ponvilawan, Nipith Charoenngam, Thanitsara Rittiphairoj, Patompong Ungprasert
No abstract available
CONCLUSIONS: Statin therapy was more effective in reducing the cumulative risks of MACE, all-cause death, and TVR in the STEMI group than NSTEMI group in Korean patients with AMI after successful drug-eluting stent implantation. PMID: 32089157 [PubMed - in process]
Data on statin use and risk of multiple myeloma is still conflicting. We performed a systematic review that comprised of terms for “statin” and “multiple myeloma” and identified 10 eligible studies for meta-analysis. The risk of multiple myeloma was significantly lower among statin-users than non-users with the pooled odds ratio of 0.80 (95% CI, 0.68 – 0.93; I2 = 72%).